SPAST and amyotrophic lateral sclerosis: Although TMED9 has not been thoroughly studied in the context of neurological disease, TMED9 has been shown to interact with wild type TDP-43, whose aggregation has been associated with the development of amyotrophic lateral sclerosis (ALS) (Redler and Dokholyan, 2012; Feneberg et al., 2020), and to associate with spastin whose mutations lead to hereditary spastic paraplegia (Reid et al., 2005).